Events Detail:

Keystone Symposium: Antibodies as Drugs / Cancer Immunology and Immunity

Antibodies as Drugs (J3)

Scientific Organizers: Paul Carter and Andreas G. Pluckthun

Dates: January 27 - February 1, 2013

Location: Fairmont Hotel Vancouver, Vancouver, British Columbia, Canada 

Antibodies have come of age as therapeutics since the late 1990s with 26 antibody therapeutics marketed in the USA and approximately 300 additional antibodies in clinical development. Many of these antibody drugs are targeted to malignant cells and are used for the treatment of a variety of cancers. Participants at this meeting will consider new therapeutic opportunities for antibodies and engineered targeting molecules across a broad range of clinical settings including oncology, autoimmunity and chronic inflammation, infectious diseases and neurology. Progress in molecular engineering to increase their clinical potential will be discussed including antibody-drug conjugates, bispecific and multispecific targeting molecules, effector function enhancement and half-life extension. New frontiers will be explored including engineering antibodies to cross the blood-brain barrier and tackling fundamental questions in antibody targeting, mechanisms of action and resistance, and immunogenicity of engineered proteins. This symposium will bring together experts from academia and industry, from molecular engineering to biomedical applications, at the forefront of advancing antibodies as drugs and will be of broad interest to scientists working in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cancer Immunology and Immunotherapy, which will share two plenary sessions with this meeting.


Source: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1198




Cancer Immunology and Immunotherapy (J4)

Scientific Organizers: Glenn Dranoff, Carl H. June, and Suzanne L. Topalian

Dates: January 27 - February 1, 2013

Location: Fairmont Hotel Vancouver, Vancouver, British Columbia, Canada

 The recent FDA approvals of Provenge® as the first therapeutic cancer vaccine and Ipilimumab® as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies.



Source: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1197